CASTLE ROCK, Colo.
July 26, 2012
AspenBio Pharma, Inc.
(Nasdaq: APPY), an
diagnostic company focused on obtaining FDA clearance and commercialization for its lead product,
, today announced that it has retained Tiberend Strategic Advisors, Inc. to manage its investor and public relations programs. Tiberend Strategic Advisors is a
New York City
-based full service corporate communications firm specializing in strategic communications for publicly traded and emerging growth companies in the healthcare sector.
, President and CEO of AspenBio, commented, "With the recent successful closing of our
offering, we are committed to maximizing the value of our company for our investors and other stakeholders. Tiberend Strategic Advisors' experience, industry focus and skills will enable us to increase our visibility within the financial and medical communities, particularly as we advance along our regulatory path, including the planned commencement of a pivotal trial of
, as well as filing for a CE Mark under the European Economic Area."
Tiberend Strategic Advisors will guide AspenBio in numerous "best practice" investor and industry communications, including the initiation of quarterly conference calls and disclosure of quantitative and qualitative performance metrics.
has significant potential to change the way appendicitis is diagnosed. No other blood-based diagnostic exists specifically for appendicitis and AspenBio is a true healthcare technology innovator," commented
, president and CEO of Tiberend Strategic Advisors. "We look forward to working with Steve and his management team to bring greater visibility to AspenBio and
, an innovative diagnostic designed to aid physicians in the evaluation of patients suspected of having acute appendicitis to allow for more conservative treatment paths."
About AspenBio Pharma
AspenBio Pharma, Inc. is an
diagnostic company focused on the clinical development and commercialization of its lead product,
is a unique blood-based test designed to aid in the identification of patients at low risk for acute appendicitis, allowing for more conservative treatment planning.
is initially being developed for pediatric, adolescent and young adult patients with abdominal pain as this population is at the highest risk for appendicitis as well having the highest risk of the long-term health effects associated with CT imaging. For more information, visit
About Tiberend Strategic Advisors, Inc.
Tiberend Strategic Advisors, Inc. (TSAI) is a full service corporate communications firm specializing in the healthcare and life sciences industry. Founded in 1989, TSAI's mission is to provide expert public and investor relations counsel to companies along the entire development lifecycle, from emerging, clinical-stage to publicly traded, revenue generating. In doing so, TSAI creates individualized platforms for companies to communicate their value proposition to those audiences that have the greatest influence on their growth and success - investors, industry stakeholders, customers and the media. For more information, visit
This press release includes "forward-looking statements" of AspenBio Pharma, Inc. ("AspenBio") as defined by the Securities and Exchange Commission ("SEC"). All statements, other than statements of historical fact, included in this press release that address activities, events or developments that AspenBio believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors AspenBio believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of AspenBio. Investors are cautioned that any such statements are not guarantees of future performance. Actual results or developments may differ materially from those projected in the forward-looking statements as a result of many factors, including our ability to successfully complete required product development and modifications in a timely and cost effective manner, complete clinical trial activities for
required for FDA submission, obtain FDA clearance or approval, complete and obtain CE Mark, cost effectively manufacture and generate revenues from
, execute agreements required to successfully advance the company's objectives, retain the management team to advance the products, overcome adverse changes in market conditions and the regulatory environment, obtain and enforce intellectual property rights, and realize value of intangible assets. Furthermore, AspenBio does not intend (and is not obligated) to update publicly any forward-looking statements. The contents of this press release should be considered in conjunction with the risk factors contained in AspenBio's recent filings with the SEC, including its Final Prospectus filed on
June 20, 2012
For Investors & Media:
Tiberend Strategic Advisors, Inc.(212) 827-0020
SOURCE AspenBio Pharma